A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Who May Qualify: - Signed willing to sign a consent form must be obtained prior to participation in the study. - Subject who are diagnosed as exon 14 skipping mutated NSCLC from tissue or plasma(ctDNA) sample analysis by treating physician (i.e. Any kind of diagnostic methods the institution currently has. Diagnostic modalities for research purpose would be also allowable.) - Subject who plan to receive Tabrecta® (Capmatinib) as per locally approved label Who Should NOT Join This Trial: - Subject with contraindication according to the locally approved label - Subject whose medical record is not accessible - Subject who are not willing to provide willing to sign a consent form Always talk to your doctor about whether this trial is right for you.